Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen and bioMerieux have signed a collaboration agreement to leverage their expertise and resources to develop a personalized approach to medicine based on Ipsen's portfolio of compounds and bioMerieux's diagnostic tests.
Subscribe to our email newsletter
Ipsen and bioMerieux have decides to co identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.
bioMerieux board member Christian Brechot said their goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly ‘patient-driven’ rather than ‘disease-driven.
Ipsen executive vice president, chief scientific officer Claude Bertrand said the shared vision and the cross-company synergies represent a unique opportunity to leverage early stage co-development of innovative products and biomarkers for patient care.